MK 386
Alternative Names: L 733692Latest Information Update: 23 May 2000
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antiacnes; Cholestanes
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne; Alopecia; Benign prostatic hyperplasia
Most Recent Events
- 23 May 2000 No-Development-Reported for Acne in USA (PO)
- 26 Nov 1998 No-Development-Reported for Benign prostatic hyperplasia in USA (PO)
- 13 Nov 1998 No-Development-Reported for Alopecia in USA (PO)